ALX Oncology Company

ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Industry:
Biopharma, Biotechnology, Health Care, Life Science, Therapeutics
Technology:
Cancer
Funding Status:
IPO
Estimated Revenue:
Less than $1M
Investors Number:
10
Headquarters:
San Francisco, California, United States
Employee Number:
11-50
Investor Type:
IPO
Total Funding:
166000000
Founded Date:
2015
Last Funding Type:
Initial Coin Offering
Last Funding Date:
2020